9 May 2024

The Dipharma Group - Experience you can trust

JPG 346 kB

The Dipharma Group is a global Contract Development and Manufacturing Organization (CDMO) and a leading manufacturer of Active Pharmaceutical Ingredients (APIs), New Chemical Entities (NCE), and advanced Intermediates for Generic and Contract Manufacturing markets, offering APIs with DMFs registered worldwide. 

Content provided by our supplier

Dipharma Francis

  • IT
  • 2015
    On CPHI since
  • 3
  • 250 - 499
Company types
Primary activities
API Producer
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Generic APIs producer
Intermediates Manufacturer

Other Content from Dipharma Francis (15)

  • News Successful FDA Inspection at Dipharma Facility in Kalamazoo, MI, USA

    Dipharma Inc. has been inspected by the US FDA and has received the EIR, satisfactorily closing the inspection process. The Company expands its range of CGMP services to include small-scale commercial APIs.
  • News Dipharma expands its Italian R&D Center to increase its analytical services

    The Company strengthens its analytical R&D capabilities, to better support its customers operating in the CDMO and Generics market.

  • Video Dipharma's CGMP pilot plant in Mereto di Tomba, Italy

    The CGMP pilot plant located in our production site of Mereto (Italy) is equipped with cutting-edge technologies, providing powerful tools to supply from early drug development up to the market. The pilot plant consists of two production lines, each equipped with 2 stainless steel and 2 glass-lined reactors and can produce batches ranging from 5 to 50 kilograms. 
    Our state-of-the-art equipment, combined with demonstrated expertise and flexibility, makes Dipharma the optimal choice to support your projects. 

  • News Dipharma completes second phase of CGMP expansion at its Kalamazoo site

    The Company continues to strengthen its capabilities in the North American market
  • Brochure Dipharma's Catalogue APIs

    Dipharma develops proprietary chemical processes and alternative solutions to support the generic API industry.Our customers can rely on a true turnkey service, where commercially competitive products are promptly conceived and manufactured in full compliance with third-party intellectual property rights.
    Along with quality, confidentiality, safety and meeting deadlines, we ensure a well-established and reliable supply chain for your peace of mind. 
    Our current product portfolio comprises over 40 high quality APIs.
  • News Dipharma receives GMP certification from Brazilian ANVISA

    The Baranzate site (Italy) is the first Dipharma manufacturing facilityto receive Anvisa certification
  • Brochure Dipharma's Exclusive Synthesis

    Achieve your goals more easily, safely and rapidly.The ability to develop innovative synthetic processes, combined with proven know-how in the handling of hazardous chemicals and reactions, makes Dipharma your optimal choice for Exclusive Synthesis services from discovery to the commercial stage.We provide you with tailor-made development and manufacturing of new and complex molecules, all the required analytical and regulatory assistance, as well as support in pre-formulation activities.
  • News Regulatory authorization for the new line at cGMP pilot plant

    Thanks to the approval by the Italian Medicines Agency (AIFA),the Company increases its efficiency and is able to face the growing demand for its services
  • News Dipharma receives EcoVadis Silver Medal

    EcoVadis has rated Dipharma Francis’s performance among the top 25% of all organizations surveyed.
  • News Merger of Kalexsyn Inc. into Dipharma Inc.

    The merger represents the last step of Kalexsyn’s integration into the Dipharma Group
  • News Kalexsyn appoints Brian Eklov as new CEO

    Kalexsyn Inc. announced that its Board of Directors appointed Brian Eklov to succeed Robert Gadwood, who is retiring, as Chief Executive Officer and Board member.
  • News Dipharma installs a new trigeneration unit

    The new plant brings significant positive impact on the environment and sustainable development
  • News Dipharma builds cGMP manufacturing suite at US subsidiary

    Italy’s Dipharma Francis has completed construction of a new cGMP manufacturing suite at its US subsidiary, Kalexsyn, strengthening its service offering and ensuring continuity across the product lifecycle from preclinical to commercialisation , the contract research and development organization announced Monday.
  • News Dipharma Francis S.r.l. announces changes in the leadership positions

    Dipharma Francis S.r.l., (Dipharma), a leading European manufacturer of Active Pharmaceutical Ingredients, announced a series of changes in the leadership positions following the retirement of Mrs. Barbara Geinoz-Biazzi, Chairman.